The chemical class known as FcRH3 Inhibitors includes a range of compounds characterized by their ability to modulate the function of FcRH3, a protein involved in key immune system processes. These compounds, while not direct antagonists of FcRH3, operate through mechanisms that influence cellular pathways and processes where FcRH3 plays a critical role. The approach to modulating FcRH3 is indirect and sophisticated, given the intricate role of FcRH3 in immune regulation, particularly in the signaling pathways of B cells. FcRH3, as part of the broader family of Fc receptor-like molecules, is implicated in modulating B cell receptor (BCR) signaling and in autoimmune responses. The indirect modulation of FcRH3 by these compounds necessitates an in-depth understanding of the protein's interactions, signaling pathways, and its influence on immune cell functions.
The primary mode of action of these compounds involves targeting mechanisms crucial for BCR signaling and immune modulation. By influencing these pathways, the compounds can indirectly affect the functionality of FcRH3. This includes modulating the activation, differentiation, and regulatory mechanisms of B cells, where FcRH3 might play a role. Additionally, since FcRH3 is implicated in immune tolerance and autoimmunity, these compounds might influence the balance between immune activation and suppression. This is particularly relevant in the context of autoimmune diseases, where dysregulation of immune responses is a key factor. The ability of these compounds to modulate FcRH3's function underscores the necessity of understanding the broader cellular context and the network of interactions that govern its activity. The development and exploration of FcRH3 modulating compounds are part of ongoing research strategies aimed at elucidating the functional roles of FcRH3 and investigating ways to influence its activity in various immune-related contexts. The capability of these compounds to modulate FcRH3's function highlights not just the complexity of targeting such a protein but also the nuanced understanding required to affect its activity within the dense web of cellular interactions and processes. Investigating these compounds provides insights into the multifaceted nature of immune regulation and the delicate balance required in modulating immune responses. Understanding the impact of these compounds on FcRH3 could lead to significant advancements in comprehending immune system dynamics an in managing conditions where immune regulation plays a crucial role.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Could possibly inhibit FcRH3 by disrupting Bruton's tyrosine kinase in BCR signaling, affecting FcRH3's modulation of B cell activation. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
Could possibly inhibit FcRH3 by affecting Syk kinase in BCR signaling pathways, potentially influencing FcRH3's role in B cell regulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Could possibly inhibit FcRH3 by affecting JAK in cytokine signaling, potentially impacting FcRH3's role in immune responses. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Could possibly inhibit FcRH3 by disrupting Src family kinases, affecting various signaling pathways, potentially impacting FcRH3's role in B cells. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Could possibly inhibit FcRH3 as an immunomodulatory drug affecting various immune responses, potentially influencing FcRH3's function in B cell regulation. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Could possibly inhibit FcRH3 by affecting immune signaling and inflammatory responses, potentially impacting FcRH3's role in immune tolerance and autoimmunity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Could possibly inhibit FCRL3 as a proteasome inhibitor affecting protein degradation pathways, potentially influencing FCRL3's stability or expression. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
Could possibly inhibit FcRH3 by disrupting PI3K in signaling pathways important for B cell survival and function, potentially affecting FcRH3's role. | ||||||
Bendamustine | 16506-27-7 | sc-357294 | 100 mg | $300.00 | ||
Could possibly inhibit FcRH3 as an alkylating agent disrupting DNA replication and repair, potentially affecting B cell function and FcRH3's role. | ||||||